Could a Low-Dose immune drug stop recurrent miscarriages?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Woman with at least 5 consecutive early miscarriages less than 14 weeks of amenorrhea and unexplained after the usual check-up; * Volunteer to participate in the trial and having given written consent after appropriate information. Exclusion Criteria: * Uterine or pelvic abnormality: uterine malformation, intracavitary fibroid, synechiae, polyp, hydrosalpinx; * Balanced translocations in both spouses; * Diabetes type I or II; * Sickle cell disease; * Contraindication to pregnancy; * Constitutional or acquired thrombophilia (protein deficit C, S, ATIII, homozygous factor V or II deficiency, antiphospholipid syndrome, antithyroid antibodies positive, celiac disease, hyperhomocysteinemia); * Ovarian insufficiency (AMH \<1 ng/ml); AFC \< 4 * Significant spermogram abnormalities and DNA fragmented more than 30% * Active HIV or HCV infection; * Main known contraindications to treatment with IL-2: * Hypersensitivity to the active substance or to any of the excipients; * Signs of progressive infection requiring antibiotic therapy; * History of organ allograft; * Pre-existing autoimmune disease; * Leukocytes \<4000 / mm3; platelets \<100,000 / mm3; hematocrit \<30%; * hepatic or renal insufficiency; * depression; * significant history or existence of a serious heart disease (in doubtful cases, perform a stress test); * patients with autoimmune disease; * patients with an infection (septicemia, bacterial endocarditis, septic thrombophlebitis, peritonitis and pneumonia); * pregnancy; * Treatment with immunomodulators, immunosuppressants (class L04A of the ATC classification), in particular systemic corticosteroids, as well as aspirin and low molecular weight heparin; * No affiliation to a social security; * Person who has already been included in this study or in another at the same time; * Major incapacitated patient (tutorship / curatorship); * Patient with an allergy to taking IL2-fd; * Participants who would present professional risk factors (eg ionizing exposure);